HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker studyVivek Naranbhai, Mary Carrington, Mathias Viard et al.|The Lancet Oncology|2021Cited by 126
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trialThomas Powles, Craig B. Davis, Xinmeng Jasmine Mu et al.|Nature Medicine|2021Cited by 115